



**RENOVO GROUP PLC**  
("Renovo" or "the Company")

**Juvista EU Phase III Trial Fully Recruited and On Schedule to Report Data in H1 2011**

Renovo Group plc (LSE: RNVO), the biopharmaceutical product company developing drugs to reduce scarring, improve wound healing and enhance tissue regeneration, today announces that in the first quarter of 2010 it completed recruitment into its first EU Phase III trial of Juvista for the improvement in scar appearance of disfiguring scars following scar revision surgery.

The trial has now recruited over 350 patients from 55 centres in 10 countries: UK, France, Hungary, Germany, Italy, Poland, Spain, Denmark, Latvia and USA.

The primary endpoint for this trial is a Clinical Panel assessment of standardised photographs at 12 months after surgery, assessed for scar improvement by the Global Scar Comparison Scale. Following the last patient visit at 12 months post surgery, the standardised photographs will be prepared, scored by an independent Clinical Panel and the data analysed, which means that Renovo is on schedule to report the results of this trial in H1 2011, as previously guided.

Renovo held a meeting with many trial investigators at the International Scar Conference in Montpellier, France 25 – 27 March 2010, the programme of which featured a number of presentations by Renovo Staff and Clinical Investigators of previous and ongoing Renovo clinical trials (no new material information was presented).

Renovo reconfirms that when the first Juvista EU Phase III trial reports in H1 2011 it expects to have a cash balance of £25 – 30M, and that it has the possibility of licensing Juvista in all countries of the world, except USA, Mexico and Canada, which are licensed to Shire.

**Professor Mark Ferguson, CEO of Renovo Group plc commented:** *"I am delighted that the first EU Phase III trial of Juvista is fully recruited, on schedule, and we look forward to the results in H1 2011."*

For further information please contact:

**Renovo**

Professor Mark Ferguson, CEO Tel No: +44 (0) 161 276 7121  
Mr David Blain, CFO Tel No: +44 (0) 161 276 7123

**Buchanan Communications**

Tim Anderson / Lisa Baderoon / Catherine Breen / Stasa Filiplic  
Tel No: +44 (0) 207 466 5000

## **About Renovo Group plc**

Renovo is a biopharmaceutical product company and a leader in the discovery and development of drugs to reduce scarring, improve wound healing and enhance tissue regeneration.

Renovo has a portfolio of products which exploit different novel mechanisms of action to reduce scarring at multiple body sites and improve healing. Renovo's lead drug for the improvement of scar appearance in the skin Juvista®, has been generally well tolerated by around 1,500 human subjects. Results from eight double-blind, placebo-controlled trials (1002, 1005, 1007, 1011, 0050, 0036, 1009 and 0042), which were designed to explore the safety and efficacy of Juvista in improving scar appearance, have provided valuable insights into safety and dose response in a variety of clinical settings. These trials met their pre-specified primary endpoints and some exploratory secondary endpoints were also significant. The first European Juvista Phase III Efficacy trial is ongoing and is due to report results in H1 2011.

Juvista® is licensed to Shire in the USA, Canada and Mexico in a deal worth up to US\$830M in upfront payments, development milestone payments and sales milestone payments plus escalating royalties on net sales. Renovo has already received upfront payments of US\$125M; the next possible milestone payments are US\$5M on commencement of the first trial for the US, US\$25M on acceptance of filing by the FDA and US\$50-150M on FDA approval, depending on the characteristics of the approved product labeling. Renovo retains rights to Juvista in all other countries of the world.

Prevascar® reported statistically significant results in a prospective, double blind, placebo controlled trial and should commence in Q2 2010 a new Proof of Concept trial for skin incisions /excisions in African Ancestral Group volunteers using an improved clinical drug product.

Adaprev™ is to be developed as a Class III medical device and the first trial for the reduction of tendon adhesions is underway and is due to report results in H1 2011.

Juvidex® is to be partnered as a cosmetic ingredient for the improvement of skin appearance and acceleration of healing.